Compare LSE & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | ALDX |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5M | 88.1M |
| IPO Year | 2023 | 2014 |
| Metric | LSE | ALDX |
|---|---|---|
| Price | $4.60 | $1.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 2.6K | ★ 834.0K |
| Earning Date | 10-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $1.07 |
| 52 Week High | $6.98 | $5.93 |
| Indicator | LSE | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 39.82 |
| Support Level | $4.15 | $1.07 |
| Resistance Level | $5.09 | $1.58 |
| Average True Range (ATR) | 0.45 | 0.10 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 50.32 | 25.00 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment, oil and gas engineering technical services, new energy production and operation, and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment, which supplies various equipment, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.